Guardant Health, Inc.

GH Healthcare Diagnostics & Research

Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.

Revenue
+36.1%
EPS
−25.7%
Free cash flow
+18.7%
Total debt
+34.8%

Quarter to September 2026, against a year earlier

154.16 14.42 −8.55%
Market cap
$20.6B
P/E
0.0×
Fwd P/E
−55.6×
Dividend yield
—
F-score
5/9
Altman Z
2.02
Beneish M
−2.78
Dividend safety
n/a

Guardant Health, Inc. (GH) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Guardant Health, Inc. (GH) trades at a EV/Sales of 16.6×. Over the past ten years it has ranged from 1.4× (October 2018) to 66.6× (June 2019); the current reading is higher than 57% of that period. That is above the Diagnostics & Research industry median of 5.2× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 13.3× 143.42%
FY2024 5.5× 5.18%
FY2023 5.2× (18.76%)
FY2022 6.4× (76.80%)
FY2021 27.7× (31.50%)
FY2020 40.4× 31.22%
FY2019 30.8× 285.22%
FY2018 8.0× 310.90%
FY2017 1.9× 0.00%
FY2016 1.9× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 19.1× 10.85%
Jun 2026 17.2× 48.57%
Mar 2026 11.6× (13.12%)
Dec 2025 13.3× 44.59%
32 more quarters

Against its own ten years

Low 1.4× High 66.6×
Ten-year median 13.7×
Current reading's percentile 57

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on GH